Lactic Acid

Lactic Acid

SCHEMBL838896

CC(O)C(=O)O.O.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1

The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lactic Acid SCHEMBL28569436 1.00 TP53 (0.92)
Lactic Acid SCHEMBL3776949 1.00 TP53 (0.92)
L-Lactic Acid SCHEMBL29408581 1.00 TP53 (0.92)
Lactic Acid SCHEMBL4350607 1.00 TP53 (0.92)
Lactic Acid SCHEMBL248090 1.00
D-Lactic Acid SCHEMBL29408597 1.00 TP53 (0.92)
L-Lactic Acid SCHEMBL5921449 1.00
Lactic Acid SCHEMBL2838779 1.00
L-Lactic Acid SCHEMBL5921377 1.00 TP53 (0.92)
Lactic Acid SCHEMBL969329 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102098921-A High-loading, controlled-release magnesium oral dosage forms and methods of making and using same WYNDEN PHARMACEUTICALS INC 2011-06-15 CN claimed
US-20090318713-A1 PROCESS FOR MANUFACTURING A CYCLIC DIESTER OF AN A-HYDROXY ACID KTANTON LTD. (IL) 2009-12-24 US claimed
US-20250381158-A1 MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS NEUROCENTRIA INC (US) 2025-12-18 US disclosed
CN-117777478-A Iron/titanium bimetal organic framework material and normal-temperature and normal-pressure preparation method and application thereof 同济大学 2024-03-29 CN disclosed
US-20240057641-A1 Beverages Comprising Salts with Improved Taste THE COCA-COLA COMPANY 2024-02-22 US disclosed
CN-113817116-B Preparation of covalent organic framework material and application of covalent organic framework material in rare earth separation 中国科学院兰州化学物理研究所 2023-03-28 CN disclosed
EP-4107215-A1 METHODS AND SYSTEMS FOR LACTIC ACID PRODUCTION AND POLYLACTIC ACID RECYCLING TripleW Ltd. (IL) 2022-12-28 EP disclosed
US-11369551-B2 Oral care compositions with improved tin compatability THE PROCTER & GAMBLE COMPANY (US) 2022-06-28 US disclosed
CN-109890464-B Oral care compositions with increased whitening efficacy 高露洁-棕榄公司 2022-04-05 CN disclosed
CN-113871586-A Controllable manganese-based layered oxide electrode material and preparation method and application thereof 武汉理工大学 2021-12-31 CN disclosed
CN-113143901-A Magnesium composition and use thereof 纽罗森特里亚股份有限公司 2021-07-23 CN disclosed
WO-2008116226-A2 MAGNESIUM COMPOSITIONS AND USES THEREOF LIU GUOSONG (US) 2008-09-25 WO disclosed
WO-2007075255-A2 MASTIC GUM COMPOSITION FOR USE AS A DIETARY SUPPLEMENT IN HUMANS AND ANIMALS INTACT ENTERPRISES, INC. (US) 2007-07-05 WO disclosed
US-20070148187-A1 MASTIC GUM COMPOSITION FOR USE AS A DIETARY SUPPLEMENT IN HUMANS AND ANIMALS INTACT ENTERPRISES, INC. (US) 2007-06-28 US disclosed
US-20050220865-A1 Compressed composition comprising magnesium salt BLAINE PHARMACEUTICALS 2005-10-06 US disclosed
EP-1263801-A1 TISSUE BULKING AND COATING COMPOSITIONS BioCure, Inc. (US) 2002-12-11 EP disclosed
EP-1263803-A1 EMBOLIC COMPOSITIONS BioCure, Inc. (US) 2002-12-11 EP disclosed
WO-2002072166-A1 COMPOSITIONS FOR DRUG DELIVERY BIOCURE, INC. (US) 2002-09-19 WO disclosed
WO-2001068720-A1 EMBOLIC COMPOSITIONS BIOCURE, INC. (US) 2001-09-20 WO disclosed
WO-2001068721-A1 TISSUE BULKING AND COATING COMPOSITIONS BIOCURE, INC. (US) 2001-09-20 WO disclosed